Immunome, Inc. $IMNM Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC reduced its position in shares of Immunome, Inc. (NASDAQ:IMNM) by 77.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 35,970 shares of the company’s stock after selling 126,198 shares during the period. SG Americas Securities LLC’s holdings in Immunome were worth $787,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. raised its holdings in Immunome by 59.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after buying an additional 5,003,824 shares during the period. Invesco Ltd. lifted its holdings in Immunome by 382.1% during the 4th quarter. Invesco Ltd. now owns 270,065 shares of the company’s stock worth $5,801,000 after buying an additional 214,049 shares in the last quarter. Virtus Investment Advisers LLC raised its stake in shares of Immunome by 16.9% in the fourth quarter. Virtus Investment Advisers LLC now owns 13,593 shares of the company’s stock valued at $292,000 after acquiring an additional 1,970 shares in the last quarter. Wellington Management Group LLP raised its position in Immunome by 267.8% in the 4th quarter. Wellington Management Group LLP now owns 934,463 shares of the company’s stock valued at $20,072,000 after purchasing an additional 680,395 shares in the last quarter. Finally, SummitTX Capital L.P. acquired a new position in Immunome during the 4th quarter worth approximately $2,741,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Wedbush reissued an “outperform” rating and set a $31.00 target price on shares of Immunome in a research report on Friday, June 12th. Wall Street Zen lowered shares of Immunome from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Immunome in a report on Wednesday, May 13th. Barclays initiated coverage on shares of Immunome in a research report on Thursday, May 28th. They set an “overweight” rating and a $36.00 price objective for the company. Finally, Truist Financial increased their target price on shares of Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, May 28th. Twelve analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Immunome presently has an average rating of “Moderate Buy” and an average price target of $33.17.

Insider Buying and Selling

In other Immunome news, insider Robert Lechleider sold 55,000 shares of the firm’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $19.85, for a total value of $1,091,750.00. Following the sale, the insider directly owned 15,805 shares of the company’s stock, valued at approximately $313,729.25. This trade represents a 77.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jean Jacques Bienaime bought 10,500 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was bought at an average price of $19.45 per share, with a total value of $204,225.00. Following the completion of the acquisition, the director owned 43,415 shares of the company’s stock, valued at $844,421.75. This trade represents a 31.90% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold 316,050 shares of company stock worth $6,578,726 in the last ninety days. 7.21% of the stock is currently owned by insiders.

Immunome Stock Down 3.0%

NASDAQ IMNM opened at $23.18 on Tuesday. The firm has a 50-day moving average price of $20.97 and a 200 day moving average price of $21.79. The stock has a market capitalization of $2.63 billion, a P/E ratio of -9.80 and a beta of 2.07. Immunome, Inc. has a 52-week low of $7.96 and a 52-week high of $27.65.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. On average, equities research analysts expect that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.